RenovoRx, Inc.RNXTNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
18.16%
↑ 84% above average
Average (22q)
9.87%
Historical baseline
Range
High:80.85%
Low:-52.42%
Volatility
1349.9%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 18.16% |
| Q2 2025 | -13.15% |
| Q1 2025 | 4.19% |
| Q4 2024 | -4.48% |
| Q3 2024 | 7.00% |
| Q2 2024 | 22.67% |
| Q1 2024 | 62.19% |
| Q4 2023 | -52.42% |
| Q3 2023 | -15.38% |
| Q2 2023 | 43.87% |
| Q1 2023 | 72.42% |
| Q4 2022 | -8.27% |
| Q3 2022 | -39.14% |
| Q2 2022 | 7.84% |
| Q1 2022 | 17.08% |
| Q4 2021 | 43.55% |
| Q3 2021 | 43.10% |
| Q2 2021 | -15.59% |
| Q1 2021 | 40.49% |
| Q4 2020 | -37.83% |
| Q3 2020 | 80.85% |
| Q2 2020 | -50.06% |
| Q1 2020 | 0.00% |